Oncogenic Fusions Involving Exon 19 of ALK  by Le, Anh T. et al.
e44 Copyright © 2012 by the International Association for the Study of Lung Cancer
Letters to the Editor Journal of Thoracic Oncology  •  Volume 7, Number 12, December 2012
Anh T. Le, BA 
Marileila Varella-Garcia, PhD 
Robert C. Doebele, MD, PhD
Department of Medicine 
Division of Medical Oncology 
University of Colorado 
Anschutz Medical Campus 
Aurora, Colorado
Oncogenic Fusions 
Involving Exon 19  
of ALK
Copyright © 2012 by the International Association 
for the Study of Lung Cancer
ISSN: 1556-0864/12/712-e44
Doi: 10.1097/JTO.0b013e31826bb94d
Penzel et al.1 recently described a lung adenocarcinoma patient with 
an EML4-ALK fusion between exon 
6 of echinoderm microtubule associ-
ated protein like 4 (EML4) and exon 19 
of anaplastic lymphoma kinase (ALK) 
(E6;A19) as a novel molecular variant. 
It should be noted that this EML4-ALK 
(E6;A19) fusion has been previously 
reported by our group in a 62-year-old 
woman also with lung adenocarcinoma.2 
The second finding of this atypical 
EML4-ALK breakpoint (the majority of 
ALK gene fusions occur at exon 20 of 
ALK) suggests that it may not be an iso-
lated event, and highlights the great diver-
sity of fusion events involving this gene. 
Furthermore, an FN1-ALK gene fusion 
was previously identified in a malignant 
stromal sarcoma patient, in which the 
fusion also occurs at exon 19 of ALK.3 
The significance of these ALK exon 19 
fusion variants is currently unknown, 
but is interesting as it expresses the ALK 
transmembrane domain. The subcellular 
localization of these exon 19-containing 
variants should be further investigated to 
better understand the implications of this 
finding; prior evidence suggests EML4-
ALK (E13;A20) is localized within the 
cytoplasm.4 Oncogenic fusions involv-
ing ROS1 and RET in lung cancer have 
been shown previously to also include 
the transmembrane domain in some 
instances.5 The patient described by our 
group demonstrated a partial response 
to crizotinib and experienced a pro-
gression free survival of approximately 
6.5-months, supporting the argument 
that these patients be considered for ALK 
inhibitor therapy like other patients who 
are positive for ALK rearrangements.2
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In Response:
We thank Le et al.1 for their comment 
on our recent article on a rare variant of 
an EML4-ALK fusion between exon 6 of 
EML4 and exon 19 of ALK. Indeed, the 
same mutation was reported by Doebele 
et al.2 shortly before our article was 
published; this was not evident to us at 
the time we prepared and submitted our 
article. The increasing detection of rare 
EML4-ALK fusions corroborates the 
great diversity of ALK translocations 
in lung cancer and raises the need to 
further investigate the tumorbiological 
significance of these rare events and the 
patients’ responses to ALK inhibitors. 
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The reported partial response to 
Crizotinib2 provides first evidence that 
patients with exon 19-containing vari-
ants of EML4-ALK might also benefit 
from ALK inhibitors.
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A Phase I Study of 
Concurrent External 
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Topotecan  
for Primary Treatment 
of Locally Advanced 
Lung Cancers
To the Editor:
The optimal treatment of patients 
with locally advanced lung cancer 
remains to be defined. Combined modal-
ity treatment, usually with concomitant 
chemotherapy and radiation therapy, 
is administered usually as definitive 
therapy for patients who are poor sur-
gical candidates. Currently, available 
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